Horiba Medical, specialists in automated in vitro diagnostic systems for haematology, haemostasis and clinical chemistry analysis, has obtained the CE mark certification for its new generation of the Microsemi CRP haematology analyser, the Microsemi CRP LC-767G.

This new generation analyser Microsemi CRP LC-767G is more compact and proposes enhanced software and network connectivity providing higher memory, usability plus a new parameter: Granulocytes-to-Lymphocytes Ratio (GLR). 

Developed by HORIBA Medical in Japan, ‘emi’ means ‘smile’ in Japanese and stands for easy to use, maintenance free and intelligent. After a successful release in Japan, this instrument is now available in Europe. This compact, easy to use addition to the Micros range, simultaneously provides a Complete Blood Count (CBC) and C-Reactive Protein (CRP) from just 18 µL of blood - all in just four minutes.

The Microsemi CRP LC-767G provides information that aims to enable quicker and more accurate medical decisions at the point of care to ultimately reduce hospitalisation times and patient costs. Its CRP analysis allows the screening of patient samples to quantify the presence of inflammation caused by bacterial, viral (e.g. COVID-19), parasites infections (e.g. Malaria) and other treatable inflammatory diseases. Also, the simultaneous access to Lymphocytes, GLR and CRP provided on this analyser is very helpful for COVID-19 patient screening, monitoring and triage. Measurement is possible immediately after blood sample collection from capillary sample, making this analyser the ideal choice for emergency testing situations.

This new Microsemi CRP LC-767G can also be used to assess infection and inflammatory conditions that require progressive observation. Its micro-sampling capabilities can be used for paediatric blood analysis, at the point of care requiring 10µL for CBC and 18 µL for CBC+CRP, and can be used with capillary, as well as venous blood samples.